Literature DB >> 8621634

Perlecan and basement membrane-chondroitin sulfate proteoglycan (bamacan) are two basement membrane chondroitin/dermatan sulfate proteoglycans in the Engelbreth-Holm-Swarm tumor matrix.

J R Couchman1, R Kapoor, M Sthanam, R R Wu.   

Abstract

The presence of proteoglycans bearing galactosaminoglycan chains has been reported, but none has been identified previously in the matrix of the Engelbreth-Holm-Swarm tumor, which is a source of several basement membrane components. This tumor matrix contains perlecan, a large, low buoyant density heparan sulfate proteoglycan, widespread in many basement membranes and connective tissues. We now identify two distinct proteoglycan species from this tumor source, which are substituted with galactosaminoglycans and which show basement membrane localization by immunohistochemistry. One species is perlecan but, in addition to being present as a heparan sulfate proteoglycan, it is also present as a hybrid molecule, with dermatan sulfate chains. A minor population of perlecan apparently lacks heparan sulfate chains totally, and some of this is substituted with chondroitin sulfate. The second species is immunologically related to basement membrane-chondroitin sulfate proteoglycan (BM-CSPG) and bears chondroitin sulfate chains. No BM-CSPG was detectable which was substituted with heparan sulfate chains. A combination of immunological and molecular approaches, including cDNA cloning, showed that perlecan and BM-CSPG are distinct in core protein structure. Both are, however, basement membrane components, although there are tissue-specific differences in their distribution.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8621634     DOI: 10.1074/jbc.271.16.9595

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  16 in total

Review 1.  Extracellular matrix molecules: potential targets in pharmacotherapy.

Authors:  Hannu Järveläinen; Annele Sainio; Markku Koulu; Thomas N Wight; Risto Penttinen
Journal:  Pharmacol Rev       Date:  2009-06       Impact factor: 25.468

2.  Maintenance of human hepatocyte function in vitro by liver-derived extracellular matrix gels.

Authors:  Tiffany L Sellaro; Aarati Ranade; Denver M Faulk; George P McCabe; Kenneth Dorko; Stephen F Badylak; Stephen C Strom
Journal:  Tissue Eng Part A       Date:  2010-03       Impact factor: 3.845

Review 3.  An enzyme in the test tube, and a transcription factor in the cell: Moonlighting proteins and cellular factors that affect their behavior.

Authors:  Constance J Jeffery
Journal:  Protein Sci       Date:  2019-05-24       Impact factor: 6.725

4.  Binding of perlecan to transthyretin in vitro.

Authors:  S Smeland; S O Kolset; M Lyon; K R Norum; R Blomhoff
Journal:  Biochem J       Date:  1997-09-15       Impact factor: 3.857

Review 5.  Iduronic acid in chondroitin/dermatan sulfate: biosynthesis and biological function.

Authors:  Anders Malmström; Barbara Bartolini; Martin A Thelin; Benny Pacheco; Marco Maccarana
Journal:  J Histochem Cytochem       Date:  2012-08-16       Impact factor: 2.479

6.  A steady-state labelling approach to the measurement of proteoglycan turnover in vivo and its application to glomerular proteoglycans.

Authors:  E L Akuffo; J R Hunt; J Moss; D Woodrow; M Davies; R M Mason
Journal:  Biochem J       Date:  1996-11-15       Impact factor: 3.857

7.  Epidermal transformation leads to increased perlecan synthesis with heparin-binding-growth-factor affinity.

Authors:  P Tapanadechopone; S Tumova; X Jiang; J R Couchman
Journal:  Biochem J       Date:  2001-04-15       Impact factor: 3.857

8.  Kinetics of chemokine-glycosaminoglycan interactions control neutrophil migration into the airspaces of the lungs.

Authors:  Yoshi Tanino; Deirdre R Coombe; Sean E Gill; Warren C Kett; Osamu Kajikawa; Amanda E I Proudfoot; Timothy N C Wells; William C Parks; Thomas N Wight; Thomas R Martin; Charles W Frevert
Journal:  J Immunol       Date:  2010-02-01       Impact factor: 5.422

Review 9.  Perlecan and tumor angiogenesis.

Authors:  Xinnong Jiang; John R Couchman
Journal:  J Histochem Cytochem       Date:  2003-11       Impact factor: 2.479

10.  Matrix-dependent plasticity of the malignant phenotype of bladder cancer cells.

Authors:  Robert E Hurst; Kimberly D Kyker; Rebecca B Bonner; Ron D Bowditch; George P Hemstreet
Journal:  Anticancer Res       Date:  2003 Jul-Aug       Impact factor: 2.480

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.